SECRETONEURIN
The missing link biomarker in cardiac testing
Welcome to CardiNor
– developing the missing link biomarker test for cardiovascular disease
– developing the missing link biomarker test for cardiovascular disease
CardiNor AS is a Norwegian biotech company recently established to handle the commercialization of Secretoneurin (SN), a new biomarker for cardiovascular disease (CVD).
Facts and figures
Latest news from CardiNor
Press release, 26.01.2023:
CardiNor enter into a distribution agreement with B.S.N. Biological Sales Network for the CE marked CardiNor Secretoneurin ELISA test
CardiNor enter into a distribution agreement with B.S.N. Biological Sales Network for the CE marked CardiNor Secretoneurin ELISA test
Press release, 10.01.2023:
CardiNor enter into a distribution agreement with Demeditec Diagnostics GmbH for the CE marked CardiNor Secretoneurin ELISA test
CardiNor enter into a distribution agreement with Demeditec Diagnostics GmbH for the CE marked CardiNor Secretoneurin ELISA test
Featured in CLI 31.10.2022:
Secretoneurin: a potential complementary cardiovascular biomarker
Secretoneurin is a novel prognostic biomarker that may predict mortality in heart failure and the occurrence of ventricular arrhythmias. Clinical Laboratory International (CLI) caught up with Professor Torbjørn Omland (University of Oslo, Oslo, Norway) to find out more about it.
Secretoneurin: a potential complementary cardiovascular biomarker